Akèy › Limfòm selil B › Maryland
Etid klinik pou Limfòm selil B nan Maryland
7 etid pou Limfòm selil B ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 4 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07652580Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 25, 2026 · NCT05389423A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Johns Hopkins University, Baltimore
- National Cancer Institute, Pediatric Oncology Branch, Bethesda
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.